Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and tolerability of BMS-986012 with cisplatin + etoposide in small cell lung cancer
jRCT2080223369Phase 1
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2016
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Atigotatug in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Primary safety and tolerability outcomes.
02
Drugs
Atigotatug
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080223369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223369.